Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. - Archive ouverte HAL Access content directly
Journal Articles Annals of the Rheumatic Diseases Year : 2010

Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (2)
1
2
3
4
5
6
7
8
9
10
11
12
13
Xavier Mariette
Michel Bardet
Antoine Martin
Thierry Schaeverbeke

Abstract

OBJECTIVE: To describe cases of lymphoma associated with anti-TNF therapy, identify risk factors, estimate the incidence and compare the risks for different anti-TNF agents. METHODS: A national prospective registry was designed (Research Axed on Tolerance of bIOtherapies; RATIO) to collect all cases of lymphoma in French patients receiving anti-TNF therapy from 2004 to 2006, whatever the indication. A case-control analysis was conducted including two controls treated with anti-TNF per case and an incidence study of lymphoma with the French population was used as the reference. RESULTS: 38 cases of lymphoma, 31 non-Hodgkin's lymphoma (NHL) (26 B cell and five T cell), five Hodgkin's lymphoma (HL) and two Hodgkin's-like lymphoma were collected. Epstein-Barr virus was detected in both of two Hodgkin's-like lymphoma, three of five HL and one NHL. Patients receiving adalimumab or infliximab had a higher risk than those treated with etanercept: standardised incidence ratio (SIR) 4.1 (2.3-7.1) and 3.6 (2.3-5.6) versus 0.9 (0.4-1.8). The exposure to adalimumab or infliximab versus etanercept was an independent risk factor for lymphoma in the case-control study: odds ratio 4.7 (1.3-17.7) and 4.1 (1.4-12.5), respectively. The sex and age-adjusted incidence rate of lymphoma was 42.1 per 100 000 patient-years. The SIR was 2.4 (95% CI 1.7 to 3.2). CONCLUSION: The two to threefold increased risk of lymphoma in patients receiving anti-TNF therapy is similar to that expected for such patients with severe inflammatory diseases. Some lymphomas associated with immunosuppression may occur, and the risk of lymphoma is higher with monoclonal-antibody therapy than with soluble-receptor therapy.
Fichier principal
Vignette du fichier
Article-RATIO-Lymphoma-anti_TNF-ARD-revision_fth.pdf (231.06 Ko) Télécharger le fichier
Vignette du fichier
inserm-00431509_edited.pdf (470.07 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00431509 , version 1 (12-11-2009)

Identifiers

Cite

Xavier Mariette, Florence Tubach, Haleh Bagheri, Michel Bardet, Jean-Marie Berthelot, et al.. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.: Lymphoma complicating anti-TNF therapy. Annals of the Rheumatic Diseases, 2010, 69 (2), pp.400-8. ⟨10.1136/ard.2009.117762⟩. ⟨inserm-00431509⟩
175 View
589 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More